LKB1 cooperates with Sox17 to drive metastasis
- 2 August 2021
- journal article
- editorial
- Published by Springer Nature in Nature Cell Biology
- Vol. 23 (8) , 816-817
Abstract
No abstract availableKeywords
Funding Information
- Ludwig Institute for Cancer Research
- Conrad N. Hilton Foundation
This publication has 11 references indexed in Scilit:
- LKB1 inactivation modulates chromatin accessibility to drive metastatic progressionNature Cell Biology, 2021
- SOX17 in cellular reprogramming and cancerSeminars in Cancer Biology, 2020
- Mammalian ISWI and SWI/SNF selectively mediate binding of distinct transcription factorsNature, 2019
- NovelSOX17frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutationsOncotarget, 2017
- The pioneer factor OCT4 requires the chromatin remodeller BRG1 to support gene regulatory element function in mouse embryonic stem cellseLife, 2017
- SOX17 is a tumor suppressor in endometrial cancerOncotarget, 2016
- LKB1 Inactivation Dictates Therapeutic Response of Non-Small Cell Lung Cancer to the Metabolism Drug PhenforminCancer Cell, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivoOncogene, 2010
- The LKB1–AMPK pathway: metabolism and growth control in tumour suppressionNature Reviews Cancer, 2009